Best Cardiac and Vascular Disorders Companies in Germany
The 102 best Cardiac and Vascular Disorders companies in Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: TRiCares.
Germany's Cardiac and Vascular Disorders sector has drawn $399 million in disclosed funding across 102 tracked companies, and not a single unicorn in the mix. That tells you something. This directory ranks the most-funded Cardiac and Vascular Disorders companies in Germany by disclosed equity and recent momentum, and the capital is concentrated in a handful of clinical-stage bets. TRiCares leads at $103 million, followed by Cardior Pharmaceuticals at $92 million and AdjuCor at $48 million. SphingoTec, OMEICOS, and 4TEEN4 Pharmaceuticals round out the top tier, together pulling another $102 million. Europa, HTGF, and the EIC Fund keep showing up as the most active backers, which signals that institutional conviction here runs deeper than it might look from the outside.
So what's actually moving? Coverage is rising, and the hot clinical themes clustering around cardiovascular hospital outcomes and age-related vascular disease are pulling more filings into view. I'd flag that the funding distribution is steep, with the top two companies alone accounting for nearly half the total pool. For you as an investor or founder mapping this market, that concentration isn't a warning sign so much as a structural reality of late-stage device and pharmaceutical development. The capital is patient, the timelines are long, and Germany's regulatory environment rewards disciplined clinical programs over early-stage noise.
Ranked: Best Cardiac and Vascular Disorders companies in Germany
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TRiCares Developer of a minimally invasive tricuspid valve replacement system. 27Funding top 21%Growth top 35%Moat top 36%Global bottom 47% All 9 signals ▾Fundingtop 21% Growthtop 35% Moattop 36% Globalbottom 47% Patentsbottom 42% Innovationbottom 36% Marketbottom 27% Techbottom 21% Newsbottom 18% Funding: Raised $103M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 27/100 | $103M | 5 mo ago | 12 | 2013 | — | DrupalPleskPHP+3 | 3 patents Patents concentrated in health & consumer products | — |
| 2 | Cardior Pharmaceuticals Developer of non-coding RNA-based therapeutics to treat cardiovascular diseases | $92M | 57 mo ago | 34 | 2016 | — | WordPressApple iCloud MailMySQL+15 | 11 patents Patents concentrated in chemistry & materials | — |
| 3 | AdjuCor Developer of biventricular assistance device for chronic heart failure | $48M | 48 mo ago | 40 40 → 25 (-38%) · sector median -21% | 2008 | — | WordPressApple iCloud MailMicrosoft 365+20 | 49 patents Implantable cardiac ventricular assist devices with expandable pumps and structured surfaces | — |
| 4 | SphingoTec Developer of biomarker-based diagnostic solutions for cancer, cardiovascular, and other diseases 55Growth top 20%Moat top 21%Funding top 32%Patents top 35% All 10 signals ▾Growthtop 20% Moattop 21% Fundingtop 32% Patentstop 35% Talenttop 38% Innovationtop 41% Globalbottom 40% Marketbottom 38% Techbottom 32% Newsbottom 18% Growth: Headcount 23 → 36 (+57%) across vintages · Fresh capital in last 24 mo Moat: Editorial + unicorn rating 7/10 · IP moat: 264 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $36M | 22 mo ago | 36 36 → 19 (-47%) · sector median -21% | 2002 | Andreas Bergmann Founder | Cart FunctionalityTYPO3 CMSPHP+13 | 264 patents Clinical biomarker assay development for kidney, sepsis, and neurodegenerative diagnostics | 4 launchs · 1 partnership |
| 5 | OMEICOS Developer of synthetic omega 3 analogues for treating cardiovascular diseases | $35M | 91 mo ago | 15 15 → 9 (-40%) · sector median -21% | 2013 | Dominik Muller Co-Founder | — | — | — |
| 6 | 4TEEN4 Pharmaceuticals Developer of therapeutics and diagnosticcs for cardiovascular diseases 35Patents top 23%Funding top 30%Innovation top 32%Moat top 32% All 8 signals ▾Patentstop 23% Fundingtop 30% Innovationtop 32% Moattop 32% Talentbottom 49% Globalbottom 40% Marketbottom 28% Techbottom 28% Patents: 88 patents matched (strict assignee match) · 63 filings since 2022 vs 25 in 2017-21 Funding: Raised $30.7M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $31M | 7 mo ago | — | 2013 | Andreas Bergmann Managing Director | WordPressMySQLPHP+9 | 88 patents DPP3-targeted therapeutics for shock, oxidative stress, and myocardial protection | 1 partnership |
| 7 | AdvanceCOR Developer of drugs and diagnostics for cardiovascular diseases | $11M | 72 mo ago | 16 | 2012 | Gotz Munch Co-Founder & Managing Director | — | 44 patents Cyclic peptide therapeutics targeting autoimmune and thyroid disorders | — |
| 8 | CardioSecur Heart health monitoring device | $9M | 112 mo ago | 14 | 2008 | — | Cart FunctionalityTYPO3 CMSOdoo+22 | — | — |
| 9 | Transcatheter Technologies Implantable devices for heart valve repair and replacement | $7M | 144 mo ago | — | 2009 | Wolfgang Goetz Co-Founder & CEO | — | — | — |
| 10 | Coramaze Mitral valve repair system | $6M | 129 mo ago | 13 | 2013 | Jochen Reinöhl Md Chief Executive Officer | — | — | — |
| 11 | Metrax Automated external defibrillators for emergencies | $6M | 201 mo ago | 77 77 → 43 (-44%) · sector median -21% | 2000 | — | Cart FunctionalityShopifyVisa+21 | 73 patents Advanced AED systems, rapid deployment logistics, and smart defibrillation electrode technologies | — |
| 12 | Preventicus Developer of medical technologies and care programs for heart health | $3M | 58 mo ago | 26 26 → 34 (+31%) · sector median -21% | 2013 | — | WordPressApple iCloud MailMicrosoft 365+27 | 30 patents Real-time physiological monitoring and analysis of cardiovascular biomarkers. | 1 launch |
| 13 | Genome Biologics Developer of therapies for cardiovascular and cardiometabolic diseases | $3M | 57 mo ago | 12 | 2016 | Jonathan Ward Co-Founder | — | 23 patents Human cardiac organoid and tissue-mimetic platforms for disease modeling and drug screening | — |
| 14 | VesselSens Provider of implantable diagnostic sensor system | $3M | 51 mo ago | — | 2016 | Alexej Domnich CEO | — | 9 patents Implantable passive RFID pressure sensors for cardiovascular monitoring and fluid dynamics measurement. | — |
| 15 | Microstim Pacer for muscle powered cardiac assistance | $3M | 153 mo ago | 5 | 2007 | Peter Klapproth Founder & CEO | — | — | — |
| 16 | ResuSciTec Therapy for cardiopulmonary resuscitation | $2M | 114 mo ago | 49 49 → 56 (+14%) · sector median -21% | 2010 | H C Beyersdorf Founder | WordPress Block EditorWordPressApple iCloud Mail+19 | 74 patents Emergency resuscitation training mannequins and extracorporeal cardiac support with therapeutic cooling systems | — |
| 17 | IEM Portfolio of devices and software for hypertension management | $759K | 65 mo ago | — | 1993 | Uwe Korth CEO | OdooPostgreSQLFirebase+9 | — | 2 partnerships |
| 18 | CalTIC Developer of TRPC inhibitors for the treatment of metabolic and pathological cardiac conditions | $289K | 44 mo ago | — | 2021 | Klaus Dinkel CEO | — | — | — |
| 19 | Redwave Medical Developer of central blood pressure monitoring device | $113K | 90 mo ago | 8 | 2017 | Verena Dittrich Co-Founder & CEO | — | 17 patents Automated blood pressure measurement and invasive hemodynamic monitoring devices. | — |
Top 12 Cardiac and Vascular Disorders companies in Germany
#1
Series D · Aschheim, Bavaria · founded 2013 · 12 employees$102.8Mraised▾
{}
- Jan 2026Conventional Debt$23.3M
- Jul 2024Series D$50M
- Sep 2022Series C$52.8M
- Nov 2021Grant (prize money)$56.4K
#2
Series C · Hennigsdorf, Brandenburg · founded 2013$30.7Mraised▾
Developer of therapeutics and diagnosticcs for cardiovascular diseases. The company is developing a targeted therapy called Procizumab to inhibit the DPP3 pathway in cardiogenic shock. It is also using a biomarker called Dipeptidyl Peptidase 3 to identify and stratify high-risk patients.
- Nov 2025Series C$63.7M
- Feb 2024Series A—
- Dec 2019Series A$7.6M
- Oct 2018Series A$23M
#3
Series C · Hennigsdorf, Brandenburg · founded 2002 · 36 employees$36.1Mraised▾
Developer of biomarker-based diagnostic solutions for cancer, cardiovascular, and other diseases. The company is involved in the development of biomarker-based in-vitro diagnostic solutions for the treatment of critical medical conditions, such as sepsis, acute heart failure, circulatory failure, and acute kidney injury. It develops a PenKid platform that measures the levels of renal hormone enkephalin and uses it to predict creatinine levels in the near future. Bio-ADM measures levels of Adrenomedullin as a biomarker for circulatory shock and vasopressor demand. It has also developed a pro-NT biomarker that measures the levels of proneurotensin to predict the risk of obesity, cardiovascular disease, and breast cancer. It provides a vr-hGH platform that measures levels of human growth hormone to predict cardiovascular risk in men.
- Aug 2024Series C$5.5M
- Dec 2019Series B$7.6M
- Oct 2018Series A$23M
- 2018Seed—
#4
Acquired · Hannover, Lower Saxony · founded 2016 · 34 employees$92.3Mraised▾
Developer of non-coding RNA-based therapeutics to treat cardiovascular diseases. The company uses oligonucleotide-based inhibitors to target molecular targets such as non-coding RNAs which have been linked to heart failure development that simultaneously control cardiac growth and calcium handling and contractility of cardiomyocytes.
- Aug 2021Series B$76M
- Jan 2019Grant (prize money)$1M
- May 2017Series A$16.3M
#5
Series B · Munich, Bavaria · founded 2008 · 40 employees$48.4Mraised▾
Developer of biventricular assistance device for chronic heart failure. The company develops extravascular devices for biventricular augmentation of the failing heart. The company uses individualized epicardial augmentation of the heart through nonblood contacting technology. It uses the imaging data to consider the specific anatomy of each patient’s heart. The implants are positioned outside the bloodstream.
- Jun 2022Grant (prize money)$3M
- Jun 2021Series B$35.1M
#6
Series C · Berlin, Berlin · founded 2013 · 15 employees$35.4Mraised▾
Omeicos is a developer of synthetic omega 3 analogues for treating cardiovascular diseases such as atrial fibrillation. The company has developed a lead compound OMT-28 based on the principle that cytochrome P450 (CYP)-dependent metabolites of arachidonic acid (AA) contribute to the regulation of cardiovascular function and the endogenous CYP-eicosanoid profile can be shifted by dietary omega-3 fatty acids. The lead candidate, OMT-28, is a synthetic small analogue of the natural omega-3 fatty acid metabolite 17,18-EEQ. The company claims that the lead analogue has shown anti-arrhythmic (phase II) and cardioprotective potential (pre-clinical) in different in-vivo experimental models.
- Nov 2018Series C$19.3M
- Oct 2017Series B—
- Mar 2017Series B$8.8M
- Nov 2015Grant (prize money)$1.9M
#7
Series A · Planegg, Bavaria · founded 2012 · 16 employees$11Mraised▾
Developer of drugs and diagnostics for cardiovascular diseases. The company's lead candidate is "Revacept", a therapeutic agent used to prevent and treat acute arterial thrombosis that can lead to heart attack and stroke. Also, it is developing GPVI-inhibiting antibodies to inhibit the attachment of platelets to the wall of a blood vessel.
- Jun 2020Series A—
- May 2016Grant (prize money)—
- 2015Series A$2.5M
- Apr 2013Series A$8.5M
#8
Funding Raised · Frankfurt Am Main, Hesse · founded 2016 · 12 employees$3Mraised▾
Developer of therapies for cardiovascular and cardiometabolic diseases. The company focuses on therapeutic target and drug discovery for illnesses lacking effective treatments. It employs technology platforms to accelerate therapy development, specifically in cardiotoxicity, heart failure, and hypertrophic cardiomyopathy. Strategies involve cellular metabolic modulation and cardiac regeneration reactivation. The company utilizes Ai-driven data analysis and preclinical organoid models for therapeutic validation.
- Aug 2021Grant (prize money)$59K
- Sep 2018Grant (prize money)$2.8M
- Sep 2017Grant (prize money)$59K
- Jun 2017Grant (prize money)$56.1K
#9
Funding Raised · Bonn, North Rhine Westphalia · founded 2016$2.8Mraised▾
VesselSens provides medical sensor solutions. The company provides an implantable sensor system for wireless restenosis detection. The system helps in diagnosing vessel clogging after surgery in real-time, along with measuring beat intervals.
- Mar 2022Grant (prize money)$2.8M
#10
Series A · Jena, Thuringia · founded 2013 · 26 employees$3.1Mraised▾
Developer of medical technologies and care programs for heart health. It provides tools for heart rhythm monitoring and analysis. The company offers programs integrating technology with medical support. It focuses on preventative care and management of cardiovascular conditions.
- Jul 2021Grant (prize money)$59.4K
- Mar 2021Grant (prize money)$246.9K
- Nov 2018Grant (prize money)$2.8M
- 2016Series A—
#11
Series B · Frankfurt, State of Hessen · founded 2008 · 14 employees$8.6Mraised▾
CardioSecur offers a mobile EKG device for monitoring heart health. Device consists of 4 disposable electrodes connected a mobile app which can record clinic-quality 15-lead ECG. App can monitor the data for any abnormalities and recommend further doctor consultation if required.
- Jan 2017Series B$5.3M
- Jan 2016Series A—
- Apr 2013Series A$3.3M
- Nov 2010Seed—
#12
Acqui-Hired · Regensburg, Bavaria · founded 2009$6.7Mraised▾
Transcatheter Technologies is a medical device company specializing in catheter-based heart valve implantation and aortic therapy. Key products in development are the transcatheter aortic valve implantation system TRINITY, the transcatheter mitral valve implant TRESILLO and the endovascular aortic repair stent TUMBAO.
- Jun 2014Series B—
- Mar 2013Series B$3.3M
- May 2011Series A$2.5M
- Jul 2009Seed$835.9K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.